Loading...
XNYS
ELAN
Market cap11bUSD
Oct 08, Last price  
22.54USD
1D
0.81%
1Q
-9.19%
IPO
-33.90%
Name

Elanco Animal Health Inc

Chart & performance

D1W1MN
XNYS:ELAN chart
P/E
—
P/S
2.39
EPS
—
Div yield, %
—
Shrs. gr., 5y
2.38%
Rev. gr., 5y
7.57%
Revenues
4.72b
+6.22%
2,909,100,0002,913,500,0002,889,000,0003,066,800,0003,071,000,0003,273,300,0004,764,000,0004,411,000,0004,417,000,0004,439,000,0004,715,000,000
Net income
-232m
L
-210,800,000-47,900,000-310,700,00086,500,00067,900,000-560,100,000-483,000,000-78,000,000-1,231,000,000338,000,000-232,000,000
CFO
560m
+3.51%
6,600,000155,900,000173,800,000487,300,000224,100,000-41,000,000483,000,000452,000,000271,000,000541,000,000560,000,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.

Related entities

Subsidiaries (3)
ELANCO INDIA PRIVATE LIMITED
ELANCO TIERGESUNDHEIT AG
ELANCO FINANCING (NETHERLANDS) B.V.

Key people

Michael-Bryant Hicks
Executive Vice President, General Counsel, Corporate Secretary · since 2018
David S. Kinard
Executive Vice President of Human Resources · since 2019
David A. Urbanek
Executive Vice President - Manufacturing, Quality · since 2018
Todd S. Young
Chief Financial Officer, Executive Vice President · since 2018
Jeffrey N. Simmons
President, Chief Executive Officer, Director · since 2018
Independent Director · since 2018
Independent Director · since 2019
Independent Director · since 2019
Michael J. Harrington
Independent Director · since 2018
R. David Hoover
Independent Chairman of the Board · since 2018
Independent Director · since 2018
Carl L. McMillian
Independent Director
David A. Ricks
Independent Director
Independent Director · since 2019
Independent Director
Joshua L. Smiley
Independent Director
IPO date
Sep 20, 2018
Employees
5,760
Domiciled in
US
Incorporated in
US
Legal address
C/O CORPORATION SERVICE COMPANY
135 NORTH PENNSYLVANIA STREET
SUITE 1600
INDIANAPOLIS, IN 46204
US
Headquarters
450 ELANCO CIRCLE
INDIANAPOLIS, IN 46221
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT